UBS Group AG Registered Ordinary Shares (UBS)

It's more than just CoreWeave's earnings beat that's lifting AMD stock today.

Nvidia has been in the news for the wrong reason lately, but investors shouldn't overlook the company's strong prospects and cheap valuation.

Lloyds Banking Group (NYSE:LYG) expects net interest income to grow at a mid-single-digit pace in 2027, slowing from this year as competition for loans and deposits continues, Chief Financial Officer William Chalmers said at the UBS European Conference. Chalmers said the bank remains confident in m

Illumina (NASDAQ:ILMN) expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS discussion. CEO Jacob Thaysen said the company remains on the trajectory outlined

Proposed Swiss capital rules could constrain the bank's global expansion, even as integration progress unlocks shareholder returns.

Danaher (NYSE:DHR) President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions, as it pursues a leadership position in life sciences and diagnostics. Speaking at a UBS conferenc

JPMorgan Chase, UBS and Stifel downgraded DraftKings after it cut its outlook. The stock is trading at its lowest level since April 2023.

What happened? A number of stocks jumped in the morning session after crude oil prices fell as President Trump played down the chance of new strikes on Iran....

A number of stocks jumped in the morning session after crude oil prices fell as President Trump played down the chance of new strikes on Iran. CNBC reported that Brent crude dropped 0.75% to $97.57 a barrel, and West Texas Intermediate slipped 0.4% to $90.45. Trump said he was highly unlikely to order fresh attacks on Iran if talks to end the conflict kept progressing. Attacks on ships near the Strait of Hormuz kept supply concerns in focus. CNBC also cited UBS, which said oil flows out of the Middle East are still elevated and are weighing on the physical market. A lower crude price can mean less cash from each barrel for oil and gas producers. That is a headwind for the energy group. Cheaper fuel can help heavy users of fuel, so the same move does not land the same way on every name in the group.

What happened? A number of stocks jumped in the morning session after crude oil prices fell as President Trump played down the chance of new strikes on Iran....

What happened? Shares of software supply chain platform JFrog (NASDAQ:FROG) jumped 3.8% in the morning session after it extended the previous session's post-...

What happened? Shares of cloud security and performance company Cloudflare (NYSE:NET) jumped 8.7% in the morning session after it extended the previous sessi...

Centrus went shopping, and Wall Street isn't happy with its purchase.

What happened? Shares of the inclusive gym franchise company (NYSE:PLNT) jumped 4.3% in the afternoon session after the company reported third-quarter fiscal...

Congressional Democrats aren’t the only one’s cheering.

A broader upswing in restaurant stocks lifted Shake Shack in October.

A Republican president overseeing a split Congress has delivered outlier S&P 500 returns since 1926.

Nearly a century of S&P 500 return data shows that a worst-case scenario is likely to unfold -- but this isn’t the complete story.

Rapidly rising R2 sales could pave the way for further gains for shareholders.

Today, Nov. 2, 2026, the EV maker surged after UBS called the selloff overdone, citing solid early R2 demand and a path to positive automotive gross margin.

It's an inauspicious start to November for this AI infrastructure specialist.

Rivian stock just got upgraded, but Lucid isn't Rivian.

What happened? Shares of electric vehicle manufacturer Rivian (NASDAQ:RIVN) jumped 8.7% in the morning session after UBS upgraded the stock to Buy from Neutr...

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

Record backlog across all segments signals sustained momentum into 2027.